Literature DB >> 12809428

Chemotherapeutics and hormesis.

Edward J Calabrese1, Linda A Baldwin.   

Abstract

This article represents the first comprehensive assessment of hormetic effects of chemotherapeutic agents. Hormetic dose-response relationships were reported for a wide range of chemotherapeutics, including antibiotics, antiviral, and antitumor agents as well as substances that affect hair growth, prostate function, cognitive performance, and numerous other endpoints. Particular attention was given to assessing the quantitative features of the dose response, the underlying mechanistic features of the biphasic nature of the dose response, and the clinical implications of hormetic responses. Recognition of the hormetic-like biphasic nature of the dose response is expected to have an important impact on the design of experiments to assess chemotherapeutics and how such agents may be employed more successfully in clinical applications.

Mesh:

Substances:

Year:  2003        PMID: 12809428     DOI: 10.1080/713611041

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  13 in total

1.  A perspective on the scientific, philosophical, and policy dimensions of hormesis.

Authors:  George R Hoffmann
Journal:  Dose Response       Date:  2009-01-19       Impact factor: 2.658

Review 2.  Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders.

Authors:  Vittorio Calabrese; Carolin Cornelius; Albena T Dinkova-Kostova; Edward J Calabrese; Mark P Mattson
Journal:  Antioxid Redox Signal       Date:  2010-08-28       Impact factor: 8.401

3.  Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes.

Authors:  Vittorio Calabrese; Carolin Cornelius; Anna Maria Giuffrida Stella; Edward J Calabrese
Journal:  Neurochem Res       Date:  2010-11-13       Impact factor: 3.996

4.  Pro-atherogenic proteoglycanase ADAMTS-1 is down-regulated by lauric acid through PI3K and JNK signaling pathways in THP-1 derived macrophages.

Authors:  Melissa-Hui-Ling Ong; Hong-Kin Wong; Tengku-Sifzizul Tengku-Muhammad; Quok-Cheong Choo; Choy-Hoong Chew
Journal:  Mol Biol Rep       Date:  2019-04-15       Impact factor: 2.316

5.  Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.

Authors:  M E Cianfrocca; K A Kimmel; J Gallo; T Cardoso; M M Brown; G Hudes; N Lewis; L Weiner; G N Lam; S C Brown; D E Shaw; A P Mazar; R B Cohen
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

6.  Hormetic Effect of Berberine Attenuates the Anticancer Activity of Chemotherapeutic Agents.

Authors:  Jiaolin Bao; Borong Huang; Lidi Zou; Shenghui Chen; Chao Zhang; Yulin Zhang; Meiwan Chen; Jian-Bo Wan; Huanxing Su; Yitao Wang; Chengwei He
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

7.  May arsenic pollution contribute to limiting Artemia franciscana invasion in southern Spain?

Authors:  Marta I Sánchez; Cathleen Petit; Mónica Martínez-Haro; Mark A Taggart; Andy J Green
Journal:  PeerJ       Date:  2016-02-18       Impact factor: 2.984

8.  Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.

Authors:  Andrew R Reynolds
Journal:  Dose Response       Date:  2010-04-23       Impact factor: 2.658

9.  In vitro erythrocyte membrane stabilization properties of Carica papaya L. leaf extracts.

Authors:  Priyanga Ranasinghe; Pathmasiri Ranasinghe; W P Kaushalya M Abeysekera; G A Sirimal Premakumara; Yashasvi S Perera; Padmalal Gurugama; Saman B Gunatilake
Journal:  Pharmacognosy Res       Date:  2012-10

Review 10.  Hormesis and its place in nonmonotonic dose-response relationships: some scientific reality checks.

Authors:  Paul Mushak
Journal:  Environ Health Perspect       Date:  2007-01-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.